MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Pacira BioSciences Operating Cash Flow 2011-2026 | PCRX
Annual Operating Cash Flow Pacira BioSciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 189 M | 155 M | 145 M | 126 M | 77 M | 70.5 M | 48.9 M | 17.8 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 189 M | 17.8 M | 104 M |
Quarterly Operating Cash Flow Pacira BioSciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 35.5 M | - | - | - | 49.1 M | - | - | - | 19.1 M | - | 103 M | - | 30.8 M | - | 103 M | - | 12.1 M | - | 30.4 M | -9.42 M | 6.21 M | - | 44.6 M | 26.3 M | 3.5 M | - | 27.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 103 M | -9.42 M | 34.4 M |
Operating Cash Flow of other stocks in the Drug manufacturers industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-11.4 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Assertio Holdings
ASRT
|
-28.2 M | $ 18.6 | -3.43 % | $ 119 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-25.9 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-99.2 M | - | - | $ 754 M | USA |
 |
Catalent
CTLT
|
268 M | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
-34.4 M | - | - | $ 50.1 M | USA |
 |
Endo International plc
ENDP
|
435 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
-4.98 M | - | - | $ 36.6 M | USA |
 |
Agile Therapeutics
AGRX
|
-9.58 M | - | 10.11 % | $ 58.2 M | USA |
 |
Harrow Health
HROW
|
43.9 M | $ 35.43 | 0.85 % | $ 1.3 B | USA |
 |
Alimera Sciences
ALIM
|
-14.3 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
-131 M | - | -23.39 % | $ 1.76 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-612 K | $ 3.07 | -0.97 % | $ 43.2 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-46.9 M | - | - | $ 2.06 B |  France |
 |
Jupiter Wellness
JUPW
|
-7.57 M | - | - | $ 33.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-462 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-43.1 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
Neoleukin Therapeutics
NLTX
|
-77.2 M | - | - | $ 193 M | Canada |
 |
Bausch Health Companies
BHC
|
1.03 B | $ 5.26 | -2.77 % | $ 1.92 B | Canada |
 |
Organogenesis Holdings
ORGO
|
14.2 M | $ 2.26 | 0.89 % | $ 298 M | USA |
 |
Aurora Cannabis
ACB
|
-211 M | $ 3.37 | -2.03 % | $ 86.3 M | Canada |
 |
Canopy Growth Corporation
CGC
|
-166 M | $ 0.99 | -2.74 % | $ 106 M | Canada |
 |
PetIQ
PETQ
|
61.9 M | - | 1.64 % | $ 400 M | USA |
 |
ProPhase Labs
PRPH
|
28.6 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-22.4 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
-1 M | - | -4.76 % | $ 65.3 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
50.7 M | - | -39.89 % | $ 27.7 M | USA |
 |
Evolus
EOLS
|
-42.3 M | $ 4.08 | -1.92 % | $ 263 M | USA |
 |
OrganiGram Holdings
OGI
|
-28.6 M | $ 1.37 | -0.72 % | $ 402 M | Canada |
 |
Emergent BioSolutions
EBS
|
-206 M | $ 7.85 | -3.09 % | $ 402 M | USA |
 |
Sundial Growers
SNDL
|
-155 M | $ 1.31 | -2.24 % | $ 3.37 M | Canada |
 |
Lannett Company
LCI
|
-7.12 M | - | 1.15 % | $ 7.11 M | USA |
 |
OptiNose
OPTN
|
-20.5 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
-32.1 M | - | -27.8 % | $ 2.56 M | USA |
 |
Relmada Therapeutics
RLMD
|
-45.8 M | $ 6.75 | -2.17 % | $ 266 M | USA |
 |
Solid Biosciences
SLDB
|
-156 M | $ 7.74 | - | $ 677 M | USA |
 |
Rockwell Medical
RMTI
|
-659 K | $ 0.95 | -1.56 % | $ 34.2 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-88 K | $ 2.21 | -4.95 % | $ 2.74 M | USA |
 |
SCYNEXIS
SCYX
|
-5.28 M | $ 0.96 | 4.57 % | $ 47.9 M | USA |
 |
Tilray
TLRY
|
7.91 M | $ 6.46 | -3.0 % | $ 3.99 B | Canada |
 |
Veru
VERU
|
-21.7 M | $ 2.48 | 3.33 % | $ 334 M | USA |
 |
Viatris
VTRS
|
2.9 B | $ 13.16 | -1.86 % | $ 15.8 B | USA |
 |
cbdMD
YCBD
|
-353 K | $ 0.72 | -2.07 % | $ 3.11 M | USA |
 |
Zomedica Corp.
ZOM
|
-17.6 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-23 M | - | - | $ 55.5 M | USA |
 |
Tricida
TCDA
|
-140 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
148 K | $ 0.64 | 3.84 % | $ 2.75 M |  China |
 |
TherapeuticsMD
TXMD
|
-159 M | $ 2.02 | -8.18 % | $ 23.4 M | USA |